Table 2.
Summary of published studies of MWA in lung tumors.
| Author, Year | Type | Therapy | Tumor | No. of Patients | Median/mean follow- up (mo) | Mean size (cm) | Median OS (mo) | OS (%) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1- year | 2-year | 3-year | 5- year | ||||||||
| Yang et al., 2014 (49) | R | MWA | Stage I NSCLC | 47 | 30.0 | – | 33.8 | 89.0 | – | 43.0 | 16.0 |
| Yao et al., 2018 (50) | R | MWA | Stage I NSCLC | 54 | – | 3.0 | 71.6 | 100.0 | – | 92.6 | 50.0 |
| Han et al., 2019 (51) | R | MWA | Stage I NSCLC | 63 | 21.0 | 2.7 | 50.0 | 97.1 | 92.6 | 63.4 | 32.6 |
| Pusceddu et al., 2019 (52) | R | MWA | Advanced NSCLC | 53 | 28.1 | 5.0 | 21.5 | 78.2 | 48.3 | 34.8 | 18.3 |
| Zhong et al., 2019 (53) | R | MWA | Advanced NSCLC | 78 | 18.0 | – | – | 93.6 | 87.7 | 71.7 | – |
| Wei et al., 2020 (54) | P | MWA & chemotherapy | Stage IV NSCLC | 148 | 13.1 | 3.6 | – | – | – | – | – |
| Wei et al., 2015 (55) | R | MWA & chemotherapy | Advanced NSCLC | 39 | 11.2 | 3.8 | 21.3 | – | – | – | – |
| Xu et al., 2022 (56) | R | MWA & DEB-BACE | ASTRI-NSCLC | 28 | 21.7 | 6.2 | 8.0 | 28.6 | – | – | – |
| Vogl et al., 2011 (57) | P | MWA | Metastatic lung tumors | 80 | – | – | – | 91.3 | 75.0 | – | – |
| Meng et al., 2021 (58) | R | MWA | Metastatic lung tumors | 32 | 32.0 | – | 36.0 | 96.9 | 75.0 | 53.3 | 17.8 |
| Iezzi et al., 2021 (59) | P | MWA | Primary and secondary lung tumors | 54 | – | 2.2 | – | 98.0 | 71.3 | – | – |
| Liu et al., 2019 (60) | – | MWA & percutaneous coaxial biopsy | Primary and secondary lung tumors | 23 | 31.0 | 1.3 | – | 91.3 | 69.6 | 60.9 | – |
MWA, microwave ablation; NSCLC, non-small cell lung cancer; DEB-BACE, drug-eluting bead bronchial arterial chemoembolization; ASTRI-NSCLC, advanced and standard treatment-refractory/ineligible NSCLC; mo, months; OS, overall survival; P, prospective; R, retrospective.